Vax-DC/MM Dendritic Cell therapeutics for multiple myeloma

Dendritic Cell

• DC is an antigen-presenting cell that helps to initiate adaptive immune responses after the innate immune system perceives antigen
• HCC reoccurs at a high probability, and clinical research for advanced hepatocellular carcinoma that there are few treatments to cure is being studied.

Features and Strong points of Vax-DC/MM

• Enhancement of the ability of migration, which is the existing immunotherapeutics' flaw, and Maximization of the induction effect on the cancer-killing ability
• verification of anticancer ability through internal and external patents and theses (domestic patent: 4, oversea patent: 1, SCI(E)-level thesis)

MM, Multiple myeloma

• MM is a disease that is considered as a three major hematologic malignancy with leukemia and shows a consistent increase globally on cases.
• Clinical trial studies are now being conducted to find a fundamental treatment for MM that has a high relapse rate and needs lifelong treatment.